Effect of oral immunomodulator Dzherelo in TB/HIV co-infected patients receiving anti-tuberculosis therapy under DOTS

International Immunopharmacology

Volumn 8, Issue 6, 2008, Pages 845-851

  Nikolaeva, Lyudmila G ^a   Maystat, Tatyana V ^a   Pylypchuk, Volodymyr S ^b   Volyanskii, Yuri L ^c   Masyuk, Lilia A ^d   Kutsyna, Galyna A ^e  

^a KHARKIV MEDICAL ACADEMY OF POSTGRADUATE EDUCATION   (Ukraine)

^b Ekomed LLC   (Ukraine)

^c The National Academy of Medical Sciences of Ukraine   (Ukraine)

^d State Department of the Penitentiary of Ukraine in Kharkov Region   (Ukraine)

^e Lugansk State Medical University   (Ukraine)

Author keywords

Herbal; HIV; Immunomodulator; Immunotherapy; Mycobacterium tuberculosis; Phytotherapy

Indexed keywords

CD16 ANTIGEN; CD20 ANTIGEN; CD3 ANTIGEN; CD56 ANTIGEN; DZHERELO; ETHAMBUTOL; IMMUNOMODULATING AGENT; IMMUNOXEL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT; VIRUS RNA;

ADD ON THERAPY; ADULT; ARTICLE; B LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL POPULATION; CLINICAL ARTICLE; CLINICAL TRIAL; COMORBIDITY; CONTROL GROUP; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; HLA SYSTEM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NATURAL KILLER CELL; PHASE 2 CLINICAL TRIAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; TREATMENT RESPONSE; TUBERCULOSIS; VIRUS LOAD;

ADMINISTRATION, ORAL; ADULT; ANTITUBERCULAR AGENTS; B-LYMPHOCYTES; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DIRECTLY OBSERVED THERAPY; FEMALE; HIV INFECTIONS; HUMANS; IMMUNOLOGIC FACTORS; KILLER CELLS, NATURAL; MALE; MIDDLE AGED; PHYTOTHERAPY; PLANT EXTRACTS; TUBERCULOSIS, PULMONARY; VIRAL LOAD;

EID: 43049122734     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2008.01.029     Document Type: Article

References (30)

1. Karachunskii M.A. Tuberculosis in HIV infection. Probl Tuberk 1 (2000) 47-52
2. Pokrovskii V.V. Treatment of HIV-infections: success or crisis?. Ter Arkh 73 (2001) 52-54
3. Reid A., Scano F., Getahun H., Williams B., Dye C., Nunn P., et al. Towards universal access to HIV prevention, treatment, care, and support: the role of tuberculosis/HIV collaboration. Lancet Infect Dis 6 (2006) 483-495
4. van der Werf M.J., Yegorova O.B., Chentsova N., Chechulin Y., Hasker E., Petrenko V.I., et al. Tuberculosis-HIV co-infection in Kiev City, Ukraine. Emerg Infect Dis 12 (2006) 766-768
5. Khauadamova G.T., Aruinova B.K., Bidaibaev N.S.H., Azhmukhanbetov K.A., Bairstanova K.A., and Bekembaeva G.S. Special features of the course of tuberculosis in HIV-infected patients. Probl Tuberk 5 (2001) 34-36
6. Nikolayevskyy V.V., Brown T.J., Bazhora Y.I., Asmolov A.A., Balabanova Y.M., and Drobniewski F.A. Molecular epidemiology and prevalence of mutations conferring rifampicin and isoniazid resistance in Mycobacterium tuberculosis strains from the southern Ukraine. Clin Microbiol Infect 13 (2007) 129-138
7. Manas E., Pulido F., Pena J.M., Rubio R., Gonzalez-Garcia J., Costa R., et al. Impact of tuberculosis on the course of HIV-infected patients with a high initial CD4 lymphocyte count. Int J Tuberc Lung Dis 8 (2004) 451-457
8. Boom W.H., Canaday D.H., Fulton S.A., Gehring A.J., Rojas R.E., and Torres M. Human immunity to M. tuberculosis: T cell subsets and antigen processing. Tuberculosis (Edinb) 83 (2003) 98-106
9. Serbina N.V., Lazarevic V., and Flynn J.L. CD4(+) T cells are required for the development of cytotoxic CD8(+) T cells during Mycobacterium tuberculosis infection. J Immunol 167 (2001) 6991-7000
10. Roy E., Lowrie D.B., and Jolles S.R. Current strategies in TB immunotherapy. Curr Mol Med 7 (2007) 373-386
11. Kaufmann S.H. Tuberculosis: back on the immunologists' agenda. Immunity 24 (2006) 351-357
12. Ershov F.I. Use of immunomodulators in viral infections. Antibiot Khimioter 48 (2003) 27-32
13. Chkhetiany R., Pylypchuk V., Argzanova O., Prihoda, Vichrova L., Zagaydanova E., et al. Comparative effect of an immunomodulator Immunoxel (Dzherelo) when used alone or in combination with antiretroviral therapy in drug-naïve HIV infected individuals. Int J Biotechnol 9 (2007) 267-276
14. Prihoda N.D., Arjanova O.V., Yurchenko L.V., Sokolenko N.I., Vihrova L.A., Pylypchuk V.S., et al. Open label trial of adjuvant immunotherapy with Dzherelo, Svitanok and Lizorm, in MDR-TB, XDR-TB and TB/HIV co-infected patients receiving anti-tuberculosis therapy under DOT. J Med Plant Res 1 (2007) 117-122
15. Melnik VP, Panasyuk OV, Pylypchuk VS, Moshich OP, Procenko NM, Leonenko OM. Deployment of herbal preparations Dzherelo and Svitanok for combination therapy of pulmonary tuberculosis. Medical Institute of Ukrainian Association of People's Medicine. Information Bulletin of the Ministry of Health. UDK:616.24-002.5-085-038:615.017. 1999, Kiev, Ukraine.
16. Zaitzeva S.I. Clinical efficacy of phytopreparation Dzherelo and its influence on the functional status of liver in patients with destructive forms of tuberculosis. Probl Ecol Med Gen Clin Immunol 71-72 (2006) 132-140
17. Rodrigues D.S., Medeiros E.A., Weckx L.Y., Bonnez W., Salomao R., and Kallas E.G. Immunophenotypic characterization of peripheral T lymphocytes in Mycobacterium tuberculosis infection and disease. Clin Exp Immunol 128 (2002) 149-154
18. Uppal S.S., Tewari S.C., Verma S., and Dhot P.S. Comparison of CD4 and CD8 lymphocyte counts in HIV-negative pulmonary TB patients with those in normal blood donors and the effect of antitubercular treatment: hospital-based flow cytometric study. Cytometry B Clin Cytom 61 (2004) 20-26
19. Kalou M., Sassan-Morokro M., Abouya L., Bile C., Maurice C., Maran M., et al. Changes in HIV RNA viral load, CD4+ T-cell counts, and levels of immune activation markers associated with anti-tuberculosis therapy and cotrimoxazole prophylaxis among HIV-infected tuberculosis patients in Abidjan, Cote d'Ivoire. J Med Virol 75 (2005) 202-208
20. Kizza H.M., Rodriguez B., Quinones-Mateu M., Mirza M., Aung H., Yen-Lieberman B., et al. Persistent replication of human immunodeficiency virus type 1 despite treatment of pulmonary tuberculosis in dually infected subjects. Clin Diagn Lab Immunol 12 (2005) 1298-1304
21. Flores-Batista V.C., Boechat N., Lago P.M., Lazzarini L.C., Pessanha L.R., Almeida A.S., et al. Low expression of antigen-presenting and costimulatory molecules by lung cells from tuberculosis patients. Braz J Med Biol Res. 40 (2007) 1671-1679
22. Bosio C.M., Gardner D., and Elkins K.L. Infection of B cell-deficient mice with CDC 1551, a clinical isolate of Mycobacterium tuberculosis: delay in dissemination and development of lung pathology. J Immunol 164 (2000) 6417-6425
23. Simonney N., Chavanet P., Perronne C., Leportier M., Revol F., Herrmann J.L., et al. B-cell immune responses in HIV positive and HIV negative patients with tuberculosis evaluated with an ELISA using a glycolipid antigen. Tuberculosis (Edinb) 87 (2007) 109-122
24. Onwubalili J.K., and Scott G.M. Natural killer cell activity in tuberculosis. Br J Dis Chest 79 (1985) 67-76
25. Ratcliffe L.T., Lukey P.T., MacKenzie C.R., and Ress S.R. Reduced NK activity correlates with active disease in HIV-patients with multidrug-resistant pulmonary tuberculosis. Clin Exp Immunol 97 (1994) 373-379
26. Nirmala R., Narayanan P.R., Mathew R., Maran M., and Deivanayagam C.N. Reduced NK activity in pulmonary tuberculosis patients with/without HIV infection: identifying the defective stage and studying the effect of interleukins on NK activity. Tuberculosis (Edinb) 81 (2001) 343-352
27. Barcelos W., Martins-Filho O.A., Guimarães T.M., Oliveira M.H., Spíndola-de-Miranda S., Carvalho B.N., et al. Peripheral blood mononuclear cells immunophenotyping in pulmonary tuberculosis patients before and after treatment. Microbiol Immunol 50 (2006) 597-605
28. Deveci F., Akbulut H.H., Celik I., Muz M.H., and Ilhan F. Lymphocyte subpopulations in pulmonary tuberculosis patients. Mediat Inflamm 2006 2 (2006) 89070
29. Tsuyuguchi I. Immunotherapy for MDR-TB (multi-drug resistant tuberculosis)-its feasibility. Kekkaku 74 (1999) 479-491
30. Pylypchuk V.S. Clinical and experimental aspects rationalizing the need for immunotherapy in the treatment of patients with tuberculosis. Probl Ecol Med Gen Clin Immunol 70 (2003) 75-84